Trefoil Therapeutics secures $5.2 million in financing

Trefoil Therapeutics has raised $5.2 million in Series 1 financing, led by Hatteras Venture Partners, according to a company press release.

The funding, along with a collaborative research agreement with the National Institutes of Health National Center for Advancing Translational Sciences Therapeutics for Rare and Neglected Diseases, will go toward research to support an investigational new drug filing for TTHX1114, the release said.

TTHX1114 is currently being developed by Trefoil as the first therapeutic application to treat Fuchs’ endothelial corneal dystrophy.

Trefoil Therapeutics has raised $5.2 million in Series 1 financing, led by Hatteras Venture Partners, according to a company press release.

The funding, along with a collaborative research agreement with the National Institutes of Health National Center for Advancing Translational Sciences Therapeutics for Rare and Neglected Diseases, will go toward research to support an investigational new drug filing for TTHX1114, the release said.

TTHX1114 is currently being developed by Trefoil as the first therapeutic application to treat Fuchs’ endothelial corneal dystrophy.